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Abstract Internal ribosome entry site (IRES)-mediated trans-
lation is a specialized mode of protein synthesis which malig-
nant cells depend on to survive adverse microenvironmental
conditions. Our lab recently reported the identification of a
group of compounds which selectively interfere with IRES-
mediated translation, completely blocking de novo IGF1R
synthesis, and differentially modulating synthesis of the two
c-Myc isoforms. Here, we examine the phenotypic conse-
quences of sustained IRES inhibition in human triple-
negative breast carcinoma and glioblastoma cells. A sudden
loss of viability affects the entire tumor cell population after
∼72-h continuous exposure to the lead compound. The
extraordinarily steep dose-response relationship (Hill-Slope
coefficients −15 to −35) and extensive physical connections
established between the cells indicate that the cells respond to
IRES inhibition collectively as a population rather than as
individual cells. Prior to death, the treated cells exhibit prom-
inent features of terminal differentiation, with marked gains in
cytoskeletal organization, planar polarity, and formation of
tight junctions or neuronal processes. In addition to IGF1R
and Myc, specific changes in connexin 43, BiP, CHOP, p21,
and p27 also correlate with phenotypic outcome. This unusual
mode of tumor cell death is absolutely dependent on exceed-
ing a critical threshold in cell density, suggesting that a
quorum-sensing mechanism may be operative. Death of puta-
tive tumor stem cells visualized in situ helps to explain the
inability of tumor cells to recover and repopulate once the
compound is removed. Together, these findings support the
concept that IRES-mediated translation is of fundamental im-
portance to maintenance of the undifferentiated phenotype
and survival of undifferentiated malignant cells.
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Introduction
General protein synthesis is accomplished by ribosomal scanning
from the 5′ end of the messenger RNA (mRNA), while internal
ribosome entry site (IRES)-mediated translation serves as a fail-
safe or emergency system-driving synthesis of proteins critical
for survival, especially under adverse conditions when general
protein synthesis is compromised [1–5]. Gene-specific transla-
tion-regulatory mechanisms such as the IRES play an extremely
important role in determining gene product levels, and
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consequently, the phenotype of the cell [6–10]. It is estimated that
10–15 % of all human genes may be translated via an IRES, but
only a small fraction of these have been identified and character-
ized [11]. Accumulating evidence suggests that malignant cells
may be particularly dependent upon IRES-mediated translation,
and may exploit this mechanism to synthesize certain growth
factor receptors, proto-oncogenes, and apoptosis-regulatory pro-
teins to promote their own survival [12–15]. We and others have
shown that IRES-mediated translation of oncogenic mRNAs
such as c-myc and IGF1R may be responsible for, or contribute
to resistance to therapy and enhanced survival of malignant cells
under suboptimal microenvironmental conditions such as those
to which tumor cells are exposed in vivo [16–18].
Our lab has sought to develop chemical probes capable of
selectively modulating IRES function. We recently reported the
identification of a group of compounds (prototype IRES inhibi-
tors) for which mechanism of action was confirmed, and effects
on the IGF1R and c-myc IRESs were examined in detail [19].
The identification of these compounds allows us to selectively
perturb IRES-mediated translation in its native context, and in-
vestigate its relationship to the malignant phenotype. Here, we
focus on the phenotypic consequences of IRES inhibition, char-
acterizing the atypical mode of cell death triggered following
continuous exposure to the lead compound.
The experiments utilize two human tumor models, triple-
negative breast carcinoma and glioblastoma, both of which are
highly undifferentiated, and for which new treatment ap-
proaches are needed to address major inadequacies in our
current therapeutic armamentarium. The results point toward
an integral relationship between IRES-mediated translation
and the undifferentiated state, demonstrating that chemical
interference with IRES function is capable of inducing a phe-
notypic shift closely resembling terminal differentiation,
which is followed closely by loss of viability affecting the
entire tumor cell population.
Materials and methods
Cells and cell culture
SUM159PT human breast carcinoma cells, which are triple-
negative (negative for estrogen receptor α, progesterone re-
ceptor, and non-amplified Her2), were obtained from
Asterand and propagated in Ham’s F-12 media supplemented
with 5 % fetal calf serum (FCS), 10 mM HEPES, 5 μg/ml
insulin, and 1 μg/ml hydrocortisone. T98G human glioblasto-
ma cells were obtained from ATCC and propagated in MEM
supplemented with 10% FCS, 1 % non-essential amino acids,
and 10 μg/ml insulin. Normal primary human mammary ep-
ithelial cells (HMEC, derived from reduction mammoplasty)
were obtained from Lonza and propagated in mammary epi-
thelial basal medium supplemented with bovine pituitary
extract, EGF, insulin, and hydrocortisone as recommended
by the supplier. 143B osteosarcoma cells were obtained from
ATCC and propagated in EMEM supplemented with 10 %
FCS. Except when deliberately varied, experiments were set
up with cells seeded at 22.5–30 % density relative to conflu-
ence (∼60–80,000 cells/cm2). Low serum conditions (0.5 %
FCS, no supplemental insulin) were frequently used to assess
the degree to which dependence on IRES-mediated translation
and sensitivity to IRES inhibition are enhanced when the mi-
croenvironment to which cells are exposed is suboptimal, e.g.,
limiting soluble growth factors. HMECs were subjected to
low growth factor conditions by diluting full propagation me-
dia 1:9 with unsupplemented basal media.
Reagents and antibodies
IRES inhibitor lead compound P (cpd_P) =N-(4-anilinophenyl)-
N′-[2-(4-chlorophenyl)ethyl]thiourea, MW 381, [19] was solu-
bilized in 100 % dimethyl sulfoxide (DMSO) to a concentration
of 10 mg/ml and used immediately or stored at −20 °C. Stock
solutions were diluted a minimum of 1:500 in media such that
final DMSO concentration did not exceed 0.2 %, which was
matched in vehicle-only control samples. Compoundswere thor-
oughly dispersed in media before adding to cells and incubating
for up to 72 h. For incubations extending beyond 72 h, media
was changed and compound re-added. For washout/recovery
assays, media was replaced (without compound) and cells
allowed 24–72 h to resume proliferation.
Antibodies: c-Myc (N262, rabbit, Santa Cruz); IGF1R (C-20,
rabbit, Santa Cruz); BiP (clone 40, mouse, BD); CHOP (L63F7,
mouse, Cell Signaling); ZO-1 (rabbit (Mid), Life Technologies,
1:100 for imaging); β-III-tubulin (TUJ1, mouse, Covance, 1:500
for imaging); connexin 43 (rabbit, Cell Signaling); PARP (rabbit,
Cell Signaling); cleaved caspase 7 (Asp198, D6H1, rabbit mono-
clonal, Cell Signaling); pRb (4H1, mouse, Cell Signaling); cyclin
D1 (H-295, rabbit, Santa Cruz); E2F1 (C-20, rabbit, Santa Cruz);
p21 (F-5,mouse, Santa Cruz); p27 (clone 57,mouse, BD); andα-
tubulin (B-5-1-2, mouse, Sigma, 1:500 for imaging). Secondary
antibodies for indirect immunofluorescence staining were
AlexaFluor 488 or 594-conjugated goat anti-mouse or rabbit
IgG (highly cross-adsorbed, Life Technologies). Actin was visu-
alized using Alexafluor 488-conjugated phalloidin. DAPI (4′,6-
Diamidino-2-phenylindole dihydrochloride) was from Sigma.
Cell viability assays
Viability endpoints were measured using standard methodol-
ogies, and readouts obtained by bioluminescence for ATP
(CellTiter-Glo, Promega), cytoplasmic protease (CytoTox-
Glo, Promega), or spectrophotometrically for MTT. Cellular
ADP was measured sequentially with ATP, following addition
of an excess of enzyme capable of converting ADP to ATP
(Abcam). Protease activity (endogenous aminopeptidase
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cleaving the Ala-Ala-Phe-aminoluciferin substrate [20]) was
assayed separately in aliquots of media (as a measure of cell
death) as well as lysates prepared from the adherent cells (as a
measure of cell viability). Appropriate negative controls (lysis
buffer alone, media alone) were subtracted from all readings.
Dose-response analyses
Viability data were analyzed and Hill slope coefficients calculat-
ed by non-linear regression using the dose response-inhibition-
variable slope (four parameters) module of GraphPad Prism 6.
Western blot assays
Whole cell lysates were prepared from treated cells as de-
scribed [19] using lysis buffer containing 4 % SDS and
720 mM 2-mercaptoethanol, preheated to 100 °C.
Equivalent aliquots of protein from each sample were separat-
ed by SDS/PAGE, transferred to 0.2 μm nitrocellulose mem-
brane, and probed with antibodies using standard immuno-
blotting procedures.
Indirect immunofluorescence staining
Cells were seeded in 8-well chamber slides (Nunc) and
allowed 48 h to recover and resume proliferation prior to treat-
ment with cpd_P or vehicle control (0.1 % DMSO) as indi-
cated in individual figure legends.
Cells were fixed with freshly prepared 2 % paraformaldehyde
X15min at room temperature, followed by permeabilizationwith
0.2%TritonX-100X10min. After washing in PBSwith 75mM
glycine and blocking in 5%normal goat serum, primary antibody
was added and incubated for 45 min to 1 h at room temperature.
Following two washes in PBS and a 10-min re-blocking step,
secondary antibodies (goat anti-rabbit IgG or anti-mouse IgG,
highly cross-adsorbed, conjugated to AlexaFluor 488 or 594,
1:200) were added and incubated for 35–45 min. Cells were
washed twice, nuclei stained with DAPI (0.2 μg/ml), and
mounted using ProLong Gold (Life Technologies).
Confocal imaging
Images were captured using a Nikon A1 confocal instrument
with 40X 1.3NA objective. In most cases, fields were random-
ly selected for imaging on the basis of DAPI staining pattern
alone (the exception being PKH26 staining of candidate tumor
stem cells, for which dedicated search for fields containing
bright red cells was necessary). Paired images of control and
experimental wells were acquired sequentially and all settings
including laser power, PMT voltage, and pinhole were held
constant between samples.
PKH26 staining
Initial staining of stock cultured cells was performed as rec-
ommended by the supplier (Sigma). Briefly, ∼4 × 106 freshly
harvested cells were incubated (in suspension) with 2 μM
PKH26 in 500 μl of Diluent C for 4 min at room temperature.
Excess dye was scavenged by addition of equal volume FCS
for 1 min, followed by three washes in 10 ml serum-
containing media, after which the cells were returned to cul-
ture. Following 7 days for propagation and mitotic dilution of
dye, cells were harvested and utilized to set up experiments.
Live cell imaging
Cells were seeded in 8-well chambered coverslips (Nunc, 400 μl
/ well) and treated with cpd_P for appropriate periods of time as
indicated on each figure. Subsequent addition of other com-
pounds (Z-VAD-fmk, necrostatin) and staining reagents
(CMXRos,Hoescht 33258)was accomplishedwithout changing
existing media, by adding diluted reagent to 200 μl aliquot of
existing media (temporarily withdrawn from well), mixing, and
then adding back to the original well. CMXRos (chloromethyl-
X-rosamine, final concentration 100 nM) and Hoescht 33258
(final concentration 2 μg/ml) were added 1 h prior to imaging.
Calcein acetoxymethyl (AM) was freshly dissolved in DMSO
for a 4 mg/ml stock solution, an intermediate dilution of
40 μg/ml prepared in media, and 5 μl of this added directly to
well 5 min prior to imaging (final concentration 0.5 μg/ml).
Calcein AM serves as an indicator of cell viability. While
the acetoxymethyl (AM) ester of calcein is not fluorescent,
esterases present within the cytoplasm of viable cells readily
cleave the AMmoiety, releasing free calcein which is fluores-
cent, producing bright green images. Chromatin condensation
accompanying cell death is associated with intense Hoescht
33258 (blue) staining of the nucleus.
Results
Prolonged exposure to IRES inhibitor cpd_P,
beyond critical thresholds in concentration and time,
results in massive loss of viability of triple-negative breast
tumor cells, with no evidence for recovery following
extended incubation in absence of the compound
We hypothesized that selective interference with IRES func-
tion would be detrimental to tumor cells which depend on
IRES-mediated translation of key oncogenic proteins such as
IGF1R and Myc for their survival. Using the human triple-
negative breast carcinoma cell line SUM159 as our initial
model, we observe that continuous exposure to IRES inhibitor
lead compound P (cpd_P) results in significant loss of viabil-
ity (Fig. 1a, b, Suppl. Fig. 1a). Three aspects of the viability
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titration are particularly notable. First, cell death is sub-acute
in nature, requiring ∼72-h continuous exposure to the IRES
inhibitor. Second, it is possible to approach complete obliter-
ation of the tumor cell population, eliminating all or very
nearly all of the tumor cells (<0.01 % cell survival). Third,
the most effective elimination of tumor cells occurs not at the
highest concentration, but at intermediate concentrations of
cpd_P (∼5 μg/ml under full serum conditions). A further in-
crease in cpd_P concentration (≥7 μg/ml) is actually less ef-
fective in terms of tumor cell eradication.
This pattern of sensitivity to cpd_P was confirmed using a
cytoplasmic protease (Promega) as an alternative endpoint for
assessing cell survival (Suppl. Fig. 1b). A perfectly reciprocal
pattern was obtained by measuring protease activity released
into the media (an indication of loss of cell membrane integ-
rity expected to accompany cell death). In fact, three distinct
measures of cell viability: ATP, cytoplasmic protease, and
MTT (as previously reported [19]) are perfectly concordant
in identifying the intermediate concentration of cpd_P as the
most effective (Suppl. Fig. 1c). The three measures of viability
are also similar in terms of temporal profiles (Suppl. Fig. 1d),
although release of cytoplasmic protease into the media clear-
ly lags behind the decline in ATP or MTT metabolic activity,
suggesting that loss of cell membrane integrity may be de-
layed in this particular mode of cell death. No significant
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(Suppl. Fig. 1e), suggesting that this mode of cell death is not
likely to involve necrosis, and may be distinct from classical
apoptosis as well (both of which are associated with increased
ADP/ATP [21]). In fact, there is actually a decrease in ADP/
ATP ratio at 48 h with higher concentrations of cpd_P.
Non-linear regression of the cpd_P titration (fitting the
curve to the canonical dose-response equation) reveals a Hill
slope coefficient of −35 (in contrast to a typical Hill slope
range of −0.4 to −4.0 associated with many anti-cancer drugs
currently in use [22, 23]). The slope of the dose-response
curve is indicative of the degree of homogeneity in response,
with a steep curve indicative of a more uniform response
across the population [23]. Thus, the extraordinarily steep
slope characterizing the cpd_P titration indicates that essen-
tially the entire population of breast tumor cells is responding
in a similar manner and in the same time frame.
Washout/recovery assays were performed to test the capac-
ity of the tumor cells to rebound and repopulate following
cessation of treatment, and examine more precisely the point
at which irreversible commitment to cell death has taken place
(Fig. 1c). Very sharp thresholds in both concentration and
duration of exposure are observed. The results indicate that,
at the optimal intermediate concentration of cpd_P (5 μg/ml),
loss of viability initiates suddenly between 48 and 72 h, and
impacts essentially the entire breast tumor cell population
within that 24-h period. Cells treated with cpd_P when either
concentration or duration of exposure is below threshold dis-
play robust recovery upon removal of the compound, indicat-
ing that transient or suboptimal IRES inhibition is reversible
and does not appear to compromise significantly the replica-
tive capacity of the tumor cells. However, cells treated beyond
these critical thresholds of both concentration and time exhibit
no evidence for recovery even following prolonged incuba-
tion in absence of the compound.
Results obtained under low serum conditions (0.5 % FCS,
no supplemental insulin) illustrate how the stress imposed by
limiting growth/survival factors increases reliance on IRES-
mediated translation and sensitivity to IRES inhibition (Suppl.
Fig. 1f). The dose-response shifts significantly (3–5-fold) to
the left, such that a cpd_P concentration of ∼1 μg/ml is now
optimal for tumor cell death. Two structural analogs of cpd_P
(P-2, P-3 [19]) were also tested, and precisely recapitulate the
biphasic pattern of response seen with the parent compound
(Suppl. Fig. 1g).
Glioblastoma cells display a similar pattern
of susceptibility to IRES inhibition
Human glioblastoma cells (T98G) respond to IRES inhibition
in almost precisely the same manner as the triple-negative
breast carcinoma cells (Fig. 1d). The titrations are marked
by a sharp threshold in concentration of cpd_P (∼7 μg/ml)
required to eliminate the tumor cells (∼99.9 % cell death by
48 h and approaching 4-log cell kill by 120 h). Loss of cell
membrane integrity and release of cytoplasmic contents (e.g.,
protease) are significantly delayed in comparison to the other
endpoints (Suppl. Fig. 2a). A similar pattern is observed under
low serum conditions (Fig. 1e), although with a significant
shift of the curve to the left, indicative of a substantial increase
in sensitivity to the IRES inhibitor. Again, the dose-response
curve is extraordinarily steep (Hill slope coefficient of −15.5,
95 % confidence interval −10.2 to −20.7), suggesting that cell
death at the optimal concentration of cpd_P is a consequence
of a specific phenotypic alteration brought about by the inhi-
bition of synthesis of critical IRES-driven proteins, and not a
typical cytotoxic response. Analogs P-2 and P-3 exhibit the
same steep dose-response profile as the parent compound
(Suppl. Fig. 1h). Not only do the tumor cells fail to recover
and repopulate once compound is removed (Fig. 1f), it ap-
pears that viability of the small fraction of remaining cells is
even further compromised during the washout/recovery peri-
od, falling as much as an additional two logs (approaching the
limit of resolution for the scale of the experiment, Suppl.
Fig. 2b).
Fig. 1 Sustained IRES inhibition results in massive loss of viability in
triple-negative breast carcinoma and glioblastoma cells. a SUM159 breast
tumor cells were treated with increasing concentrations (0–10 μg/ml) of
IRES inhibitor cpd_P for periods of 24 to 120 h. Cell survival is assessed
using ATP (CellTiter-Glo) as endpoint, presented relative to vehicle
(0.1 % DMSO) control (=100 %), plotted on a logarithmic scale. All
data ± SEM. b Tight dose-response titration for SUM159 cells treated
with cpd_P in full serum. Assay endpoint is ATP at 72 h. Shown are the
actual data ± SEM in triplicate. The most comprehensive tumor cell death
is obtained at intermediate concentrations of cpd_P between 3 to 6 μg/ml.
As the cpd_P concentration approaches this intermediate range, an
extremely sharp decline in cell viability is evident (note near 1000 fold
decrease in viability between 2.5 and 3.0 μg/ml cpd_P). Non-linear
regression was used to fit the data to standard 4-parameter (variable slope)
dose-response equation. Hill Slope Coefficient = −35.09 (95 %
confidence interval −37.63 to −32.54), R square = 0.9987. c Washout/
recovery assay measuring capacity of SUM159 cells to repopulate
following exposure to IRES inhibitor. Cells were treated with cpd_P at
variable concentrations (range 0–10 μg/ml) for variable periods of time
(range 24–120 h). Compound was then removed and cells allowed 72 h to
recover and resume proliferation. d T98G glioblastoma cells were treated
with increasing concentrations (0–14 μg/ml) of cpd_P (or vehicle
control = 0.14 % DMSO) for varying periods of time as indicated. Cell
survival is assessed using ATP as endpoint (logarithmic scale). All data ±
SEM. (e) Tight dose-response titration for T98G cells treated with cpd_P
under Low serum conditions (0.5 % FCS, no supplemental insulin), over
the range 0.8 to 5 μg/ml. Assay endpoint is MTT at 72 h. The data were
analyzed by non-linear regression to fit the standard 4-parameter (variable
slope) dose-response equation. Hill Slope coefficient = −15.51 (95 %
confidence interval = −20.79 to −10.22), R square = 0.9811. f Washout/
recovery assay for T98G cells treated with increasing concentrations of
cpd_P (range 0–14μg/ml) for varying periods of time (range 24 to 120 h).
Following treatment, compound was removed and cells allowed an
additional 72 h to recover and resume proliferation. Endpoint is ATP,
plotted on logarithmic scale. Note the sharp thresholds in concentration
and duration of exposure required for irreversible elimination of the tumor
cells
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Normal cells are resistant to IRES inhibition
Although it may be pathologically activated in undifferentiat-
ed tumor cells, under normal physiological conditions, the c-
myc IRES is utilized primarily during early embryonic devel-
opment, and is essentially inactive in normal differentiated
adult tissues [12]. Consequently, it is reasonable to postulate
that normal cells might not be reliant on IRES-mediated trans-
lation, and might not be adversely affected by prolonged ex-
posure to an IRES inhibitor. To test this, normal primary hu-
man mammary epithelial cells (HMECs) were treated with
IRES inhibitor cpd_P for 72 h under either full (growth factor
supplemented) or low (growth factor deprived) conditions.
Little or no loss of viability of the normal cells was observed
(Suppl. Fig. 2c, d). In contrast, malignant osteosarcoma cells
(143B) display a pattern of sensitivity to IRES inhibition that
closely resembles that of the SUM159 breast carcinoma and
T98G glioblastoma cells (Suppl. Fig. 2e, f). Thus, it appears
that while IRES inhibition can be highly detrimental to undif-
ferentiated tumor cells which depend on IRES-mediated trans-
lation for their survival, normal cells may tolerate such a
treatment.
IRES inhibition causes cells to display features of terminal
differentiation prior to synchronized loss of viability
SUM159 triple-negative breast tumor cells early in the course
of treatment with IRES inhibitor cpd_P exhibit dramatic alter-
ations in structural organization and spatial orientation
(Fig. 2a, Suppl. Fig. 3). The α-tubulin staining pattern is
a DMSO (Full serum) cpd_P (5 g/ml) cpd_P (7 g/ml) cpd_P (10 g/ml)
b
c
DMSO cpd_P (5 g/ml) cpd_P (7 g/ml) cpd_P (10 g/ml)cpd_P (3.5 g/ml)
cpd_P
(5 g/ml)
Fig. 2 IRES inhibition induces marked gains in structural organization
and intercellular networking of breast tumor cells. a α-tubulin staining
(red) and confocal imaging of SUM159 breast tumor cells treated under
full serum conditions for 36 h with IRES inhibitor cpd_P at the indicated
concentrations. b Phase contrast images of SUM159 cells continuously
exposed to cpd_P at concentrations ranging from 0 to 10 μg/ml for 72 h
under full serum conditions. Note the highest degree of structural
organization and most comprehensive cell death is obtained at
intermediate concentration of cpd_P (5 μg/ml). Also note the
homogeneous morphology at 5 μg/ml versus the bimorphic appearance
of cells treated at 7–10 μg/ml cpd_P. c Phase contrast images of SUM159
cells treated with 5 μg/ml cpd_P for 60 h under full serum conditions,
demonstrating extensive intercellular connections formed in response to
IRES inhibition. The image on the right was obtained at low
magnification and demonstrates the tendency of this network of dead cell
corpses to peel off the growth surface as an intact sheet. Scale bars
50 μm (a, b); 100 μm (c)
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indicative of a more highly developed cytoskeleton. The cells
also demonstrate a propensity to form distinct circular struc-
tures, with remarkably well-rounded concave surfaces sur-
rounding open spaces (evidence of planar polarity), and form
extensive connections with neighboring cells. By contrast, the
vehicle-treated cells exhibit only diffuse cytoplasmic α-
tubulin staining and remain haphazardly distributed on the
growth surface, with little or no evidence of intercellular in-
teraction or polarity.
As cells approach 72-h continuous exposure to cpd_P at
the optimal concentration of 5 μg/ml, a profound loss of cy-
toplasmic volume is observed accompanying loss of viability,
yet the nucleus retains its round contour, and the intercellular
connections between the cell corpses remain intact (Fig. 2b,
middle panel). The end result is a vast network of intercon-
nected circular structures resembling a chain-link fence, cov-
ering the entire growth surface (Fig. 2c). The homogeneous
appearance of the cells correlates with the comprehensive loss
of viability as documented in Fig. 1. The cells do not detach
individually from the growth surface as is typical of apoptosis
or programmed necrosis, but remain attached. Eventually, the
network of interconnected dead cell corpses peels off as an
intact sheet, in a manner reminiscent of desquamation. This
helps to explain the delay in release of cytoplasmic contents
(e.g., protease) noted earlier, in that loss of cell membrane
integrity and cellular disintegration are not key features of this
mode of cell death.
Note that the highest degree of structural organization and
intercellular connectivity is observed at the intermediate concen-
tration of cpd_P (5 μg/ml in full serum). Cells treated with lower
concentrations of cpd_P show signs of increased cellular inter-
dependence and structural organization, but on a considerably
more limited scale, and with little or no loss of viability. Cells
treated with higher concentrations of cpd_P (e.g., 7–10 μg/ml)
beyond the window for optimal cell death are less highly-
organized and loss of viability, while extensive, is not compre-
hensive, as a subpopulation of relatively resistant or at least more
slowly dying cells can readily be seen. These findings are con-
sistent with the biphasic viability data presented in Fig. 1.
Glioblastoma cells subjected to IRES inhibition also
exhibit marked gains in structural organization
and formation of an extensive intercellular network
Perhaps surprisingly, the morphological changes observed in
T98G glioblastoma cells treated with IRES inhibitor cpd_P
closely resemble those seen in the triple-negative breast tumor
cells. Confocal imaging of α-tubulin staining patterns again
documents a marked gain in cytoskeletal organization both
within the individual cells as well as overall tissue architecture
(Fig. 3a). When treated with optimal (intermediate) concen-
trations of cpd_P (e.g., 2.5 μg/ml in low serum), many of the
glioblastoma cells adopt a wiry appearance, developing long
processes, suggestive of neuronal differentiation (Fig. 3b).
The cells display increased intercellular connectivity, forming
a tight network that, much like that formed by the breast tumor
cells, remains attached to the growth surface, eventually peel-
ing off as an intact layer.
Although the quantitative distinction in cell death outcomes
between intermediate and higher concentrations of cpd_P is not
as marked in the glioblastoma cells as with the breast tumor cells
(compare Fig. 1b to Fig. 1e), the morphological distinction be-
tween these phenotypic outcomes is startling (Fig. 3b, middle
panels), as cells treated with cpd_P at concentrations beyond the
optimal window for differentiation exhibit gross osmotic swell-
ing and widespread detachment of individual cells.
Critical threshold in cell density required for triggering
of synchronized, comprehensive tumor cell death
The fact that the mode of cell death induced by intermediate
concentrations of IRES inhibitor cpd_P appeared to be syn-
chronized and comprehensive in nature, with essentially all of
the cells undergoing a dramatic phenotypic shift characterized
by features of terminal differentiation, followed by massive
loss of viability, suggested that this was a highly orchestrated
event, in which the population of malignant cells responded as
a unit. Furthermore, the extensive intercellular connections
established (so structurally sound as to be retained even fol-
lowing cell death) suggested that communication and interac-
tion among the population of cells might be a key to executing
this phenotypic alteration and the subsequent loss of viability.
To test this hypothesis, a series of experiments was performed
in which cell death outcome in response to IRES inhibition was
titrated as a function of cell density. The results obtained for both
SUM159 breast tumor cells (Fig. 4a, Suppl. Fig. 4a) and T98G
glioblastoma cells (Fig. 4b, Suppl. Fig. 4b) clearly indicate that
there exists a very sharp threshold in cell density which is re-
quired in order for the synchronized, comprehensivemode of cell
death to take place. SUM159 cells seeded at ≥15 %
(∼40,000 cells/cm2) precisely recapitulate the biphasic viability
patterns described in Figs. 1 and 2, with essentially complete
elimination of the population (≥99 % cell death) at the optimal
cpd_P concentration of 5 μg/ml. However, cells seeded at just
half that density (7.5 %) are affected but not comprehensively
eliminated, and cells seeded at 3% are essentially resistant to cell
killing by cpd_P. A similar relationship between cell density and
susceptibility to IRES inhibition is observed in the T98G glio-
blastoma cells, where cells seeded at 11.25 % (∼45,000 cells/
cm2) are almost completely eliminated (0.6 % survival) follow-
ing 72-h exposure to 7 μg/ml cpd_P, but cells seeded at half that
density (5.625 %) are completely resistant (92.8 % survival) to
the same treatment. These results indicate that the unique mode
of cell death observed at intermediate concentrations of cpd_P is
a population event.
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This requirement for a minimum number or density of cells is
consistent with the physiological purpose of terminal differenti-
ation, a program executed by a population of cells intended to
form a functional tissue. It is a fundamental principle of devel-
opment that terminal differentiation should normally not be ini-
tiated until a sufficient number of progenitor cells have accumu-
lated to form the intended tissue or organ. This apparent moni-
toring of cell number or population density by the tumor cells is
highly reminiscent of the quorum-sensing mechanisms utilized
by bacteria to coordinate population-wide changes in phenotype.
Quorum sensing is a form of intercellular communication which
allows unicellular prokaryotic organisms to respond synchro-
nously to alterations inmicroenvironment, almost as if they were
a multicellular organism [24, 25]. The involvement of quorum-
sensingmechanisms in human tumor cell biology andmetastasis
has been hypothesized [26, 27].
Further evidence of terminal differentiation induced
by IRES inhibition: formation of tight junctions
and neuronal processes
In vehicle-treated SUM159 cells, low-level ZO-1 immunoreac-
tivity is spread diffusely throughout the cytoplasm; however, in
cells exposed to cpd_P, brightly stained discrete ZO-1-
containing foci are present at points of intercellular contact, sug-
gestive of the formation of functional tight junctions, a feature of
differentiated epithelia (Fig. 5a, Suppl. Fig. 5). Interestingly, cells
treated with cpd_P at the optimal concentration of 5 μg/ml dis-
play multiple ZO-1 positive foci per cell and make multiple
contacts with adjacent cells in the context of round acinar struc-
tures. The cells exposed to higher concentrations of cpd_P only
display 1 or 2 ZO-1 foci per cell, and the intercellular connec-
tions are correspondingly more restricted in these cells.
The wiry morphology and marked gain in intercellular con-
nectivity observed in T98G cells treated with cpd_P is made
particularly evident upon staining for β-III tubulin, a specific
marker of neuronal differentiation (Fig. 5b). Vehicle-treated con-
trol cells are roughly trapezoidal in shape; however, when treated
with cpd_P, the cells develop very long processes typical of
differentiated neurons. Some of these processes are particularly
large in diameter, while others display a branching morphology.
Together, these findings support the conclusion that IRES inhi-
bition has the potential to induce a dramatic phenotypic alteration
consistent with terminal differentiation, even in what originally
were highly undifferentiated malignant cells.
Specific changes in Myc, IGF1R, BiP, CHOP,
and connexin 43 correlate with phenotypic outcome
of IRES inhibition
Western blot analyses reveal dynamic alterations in key mol-












Fig. 3 IRES inhibition induces
marked gains in structural
organization and intercellular
networking of glioblastoma cells.
a α-tubulin (red) staining patterns
in T98G glioblastoma cells
treated under full serum
conditions for 48 h with IRES
inhibitor cpd_P at the indicated
concentrations. b Phase contrast
images of T98G cells exposed to
cpd_P for 48 h under low serum
(0.5 % FCS) conditions. Note the
distinct phenotypic outcomes
associated with the intermediate
(2.5 μg/ml) versus high (5 μg/ml)
concentrations of cpd_P. The
image in the upper right panel
was obtained at low
magnification of cells treated with
2.5 μg/ml cpd_P, and
demonstrates the tendency of
these cells to peel off the growth
surface as an intact sheet. Scale
bars 50 μm (except for b) upper
right = 100 μm
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and elucidate the basis for the thresholds and transitions be-
tween these outcomes (Fig. 6a).
Dynamic alterations to Myc translation are observed in the
SUM159 breast tumor cells, with a shift from synthesis of the
dominant oncogenic isoform p64 to the minor isoform p67,
which has been attributed potent growth inhibitory properties
[29]. The most complete shift to p67 occurs at the optimal
concentration of 5 μg/ml cpd_P. By 48 h, cells treated across
the range of 5–10 μg/ml cpd_P exhibit exclusively the p67
isoform, and at 72 h, even the level of p67 diminishes such
that very little Myc protein remains in these cells. The pattern
observed under low serum conditions is similar (Suppl.
Fig. 6a).
For T98G, essentially all Myc protein is lost from the
cpd_P-treated cells (Fig. 6b, Suppl. Fig. 6b). Under low serum
conditions, the cells display evidence of attempts to counteract
the perpetual interference with IRES-mediated translation of
Myc. At 1.75 μg/ml cpd_P, Myc is transiently superinduced,
perhaps by shifting c-myc transcription to use of a different
mRNA isoform. Cells treated with ≥2.5 μg/ml cpd_P exhibit
low level synthesis of MycS, a naturally-occurring N-termi-
nally truncated isoform generated by translation initiation at
either of two downstream AUG codons within exon 2 [28].
Apparently, neither of these attempts to circumvent the block
to IRES-mediated translation of Myc is sufficient to salvage
the cells, as a 4 to 5 log cell kill is observed in each of these
situations (Suppl. Fig. 2b).
As Myc is tightly associated with maintenance of the un-
differentiated phenotype [30, 31], the change in Myc transla-
tion leading to the depletion ofMyc protein is almost certainly
one of the key factors triggering terminal differentiation and
synchronized death in the breast tumor and glioblastoma cells
subjected to IRES inhibition.
In SUM159 cells under full serum conditions, there is little
turnover of existing IGF1R, and minimal requirement for de
novo IGF1R synthesis, thus inhibition of IRES-mediated
translation has little or no perceptible impact (Fig. 6a).
When serum deprived, however, the SUM159 cells are stim-
ulated to increase synthesis of IGF1R in attempt to more ef-
fectively capture limiting soluble ligand (IGF-1 and IGF-2) in
the media. This increase in rate of translation of the IGF1R
mRNA depends on the IRES, and a concentration-dependent
effect of cpd_P on IGF1R is revealed (Suppl. Fig. 6a).
IGF1R decreases in a concentration-dependent manner un-
der both full and low serum conditions in T98G cells treated
with cpd_P. Interestingly, the optimal cell death outcomes are
observed under conditions in which IGF1R is reduced but not
eliminated. It is possible that a certain level of IGF1R is re-
quired to facilitate induction or execution of the terminal dif-
ferentiation program [32].
Connexin 43 (cx43, gap junction protein alpha 1) was of
interest as a potential contributor (via gap junctional intercel-
lular communication [33, 34]) to the coordinated responses to
IRES inhibition exhibited by both the breast tumor and glio-
blastoma cells. Like IGF1R and c-myc, the cx43 mRNA has
been shown to contain an IRES [35, 36], and in the T98G
cells, the western blot analyses reveal a clear concentration-
dependent decrease in cx43 levels. The loss of cx43 at the
higher concentrations of cpd_P and the resulting impairment
in intercellular communication could conceivably contribute
to the inability of these cells to fully execute the population-
wide terminal differentiation program, thus leading to death
by alternative, less comprehensive (i.e., cell autonomous)
mechanisms.
BiP (immunoglobulin binding protein, glucose-regulated
protein 78 kDa, GRP78), which is involved in translation
quality control [37, 38], is induced by cpd_P in the SUM159
breast tumor cells in roughly a concentration-dependent man-
ner. Curiously, however, there is a de-induction of BiP at the


















































Fig. 4 Titration of cell density and its effect on susceptibility to IRES
inhibition. SUM159 breast tumor cells (a) or T98G glioblastoma cells (b)
were seeded at varying densities, allowed 48 h to recover and resume
proliferation, then treated with IRES inhibitor cpd_P at varying
concentrations for 72 h. Relative cell survival is plotted versus cpd_P
concentration, where each line represents a different initial seeding
density. Blue above threshold density, conducive to terminal
differentiation and susceptible to synchronized, comprehensive cell
death triggered by IRES inhibition; red below threshold, resistant to
intermediate concentrations of cpd_P; green very low (clonogenic)
density. All data ± SEM
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phenotypic shift toward terminal differentiation. A key medi-
ator of cell death triggered by translational stress (i.e., down-
stream of BiP) is CHOP (CCAAT/enhancer-binding protein
homologous protein, DNA damage inducible transcript 3 [39,
40]). Marked CHOP induction is observed at the higher con-
centrations of cpd_P in both the SUM159 and T98G cells.
However, CHOP (much like BiP) is selectively de-induced
and nearly eliminated at the intermediate concentrations
where cpd_P most effectively induces terminal differentiation
and synchronized death (also see Suppl. Fig. 7). It is possible
that CHOP expression is deliberately repressed by the cells to
facilitate execution of the terminal differentiation program,
which may take precedence over responding to translational
stress. The high levels of CHOP observed at higher concen-
trations of cpd_P may be responsible at least in part for sub-
stitution of the differentiation-associated population-wide cell
death event with a more progressive cell autonomous mode of
cell death.
p53 is mutated in both SUM159 and T98G. However, RB1
appears to be intact in each of these cell lines, thus compo-
nents of the RB1 pathway were examined. In SUM159 cells,
dynamic alterations are exhibited in E2F1, first increasing,
then decreasing across the titration. Reciprocal changes ob-
served in cyclin D1 may reflect an attempt to compensate
for the alterations in E2F1 levels. In T98G cells, E2F1 de-
creases with increasing concentration of cpd_P, but only in
full serum. By 72 h, both E2F1 and cyclin D1 are substantially
decreased in the treated cells (in both full and low serum).
Overall, however, there does not appear to be a clear
consistent relationship between variations in cyclin D1 or
E2F1 levels and the cell death outcome elicited by cpd_P.
Perhaps surprisingly, the CDK inhibitors p27 and p21 ex-
hibit marked decreases in the breast tumor and glioblastoma
cells subjected to IRES inhibition. In SUM159, p27 (much
like CHOP) is diminished most dramatically at intermediate
concentrations of cpd_P, in cells undergoing terminal differ-
entiation and synchronized death. In T98G cells in full serum,
the decrease in p27 is greatest at intermediate concentrations
of cpd_P, while in low serum, p27 decreases in a time and
concentration-dependent manner across the entire titration.
p21 is completely eliminated from both cell lines following
greater than or equal sign 48-h exposure to cpd_P.
Myc inhibits the expression of p21 and p27, so the loss of
Myc would be expected to increase rather than decrease these
proteins. Furthermore, p27 often increases as cells become
quiescent, p21 is expected to increase in response to stress,
and both p21 and p27 facilitate terminal differentiation. The
fact that neither of these CDK inhibitors increases in the treat-
ed cells, rather both exhibit a pronounced decrease in expres-
sion, suggests that IRES inhibition disrupts the normal phys-
iological responses expected of these proteins, and the func-
tional incompatibilities generated could contribute to the com-
prehensive cell death outcome observed in these cells.
Further supporting the conclusion that cell death induced
by IRES inhibitor cpd_P is atypical, we observe no activation
of caspase 7 (commonly involved in response to translational
stress) and no significant PARP cleavage, in either cell line
under any treatment condition (except for T98G cells exposed
a
b
DMSO (Full serum) cpd_P (5 g/ml) cpd_P (10 g/ml)
ZO-1  DAPI
DMSO (Full serum) cpd_P (7 g/ml) cpd_P (14 g/ml)
  tubulin  DAPI 
Fig. 5 Evidence of terminal
differentiation in breast tumor and
glioblastoma cells subjected to
IRES inhibition: formation of
tight junctions and neuronal
processes. a SUM159 breast
tumor cells treated with cpd_P at
5 or 10 μg/ml for 48 h under full
serum conditions, then stained for
ZO-1 (Tight Junction Protein 1,
red). Focal distribution of ZO-1 in
treated cells is consistent with
formation of tight junctions. b
T98G glioblastoma cells treated
with cpd_P at 7 or 14 μg/ml for
48 h under full serum conditions,
then stained for β-III tubulin (a
marker of neuronal
differentiation, green). Scale
bar = 25 μm (a); 50 μm (b)
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to 1.75 μg/ml cpd_P for 72 h under low serum conditions,
which follows the superinduction of Myc). Attempts to detect
caspase 3/7 activation by confocal imaging using a fluorescent
substrate yielded equivocal results at best (data not shown),
suggesting that caspase activation if present is limited. This
lack of conventional biochemical indicators of programmed
cell death fits with the atypical kinetic and morphological
characteristics of death induced by cpd_P.
Live cell imaging confirms sudden death triggered
as a consequence of sustained IRES inhibition
Live cell imaging was carried out on SUM159 cells to en-
hance our characterization of the atypical mode of cell death
associated with IRES inhibition. The cells treated with cpd_P
exhibit readily perceptible gains in structural organization and
intercellular connectivity within the first 24 h (Fig. 7a), and
through 48 h, the cpd_P-treated cells remain viable and ac-
tively metabolizing calcein AM (producing green fluorescent
signal). Chromatin remains in an open configuration, appar-
ently facilitating execution of the terminal differentiation
program.
The images captured at 72 h demonstrate how suddenly
and dramatically cell status has changed. The cells are no
longer viable, as there is very little calcein AM metabolism,
and what little green staining is present is highly dysmorphic
and restricted to subcellular pockets of esterase-positive ma-
terial. Virtually all nuclei now exhibit gross chromatin con-
densation (manifested as intense Hoescht 33258 (blue) stain-
ing). Intercellular connections appear to remain intact, though
none of the markers being used for live cell imaging is ideally
suited for visualizing the structural components of the network
of dead cell corpses.
Figure 7b documents that any adverse consequences of
IRES inhibition up to the 48-h time point are reversible, as
cells in which the compound was removed at that time rapidly
regain the morphology and staining pattern typical of vehicle-
treated control cells. In contrast, neither the caspase inhibitor
Z-VAD-fmk or the inhibitor of programmed necrosis
necrostatin added at the 48-h time point mitigates the
population-wide cell death event that takes place between 48
and 72 h. Although accelerated somewhat compared to the
breast tumor cells, a similar outcome is observed with live cell
imaging of the T98G glioblastoma cells (Fig. 7c).
Fig. 6 Molecular correlates of tumor cell death induced by IRES
inhibition in SUM159 breast tumor cells and T98G glioblastoma cells.
a Composite western blot results obtained from whole cell lysates
prepared from SUM159 cells treated with varying concentrations of
cpd_P for 24, 48, or 72 h under full serum (5 % FCS, 5 μg/ml insulin)
conditions. Myc 2 (p64) is the dominant (oncogenic) isoform of c-Myc.
Myc 1 (p67) is the minor (growth inhibitory) isoform of c-Myc. b
Composite western blot results obtained from whole cell lysates
prepared from T98G cells treated with varying concentrations of cpd_P
for 24, 48, or 72 h under low serum (0.5 % FCS, no supplemental insulin)
conditions. MycS is generated by translation initiation at either of two
closely spaced internal methionine codons within exon 2 [28]
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In situ visualization of the death of putative tumor stem
cells as a result of sustained IRES inhibition
Because cells treated with optimal concentrations of cpd_P
display no capacity to recover or repopulate, this suggested
that putative tumor stem cells, which typically represent the
most resilient subset of malignant cells, may also have been
eliminated in the course of the population-wide cell death
event. To address this issue, a series of experiments were
performed in which putative tumor stem cells were identified
in situ on the basis of retention of the tracking dye PKH26
[41]. Stock SUM159 cells were stained briefly with the dye
and then allowed 1 week (one full passage) to proliferate,
during which those cells that divide would distribute the dye
equally to their daughter progeny, while putative tumor stem
cells, which characteristically divide very infrequently, would
remain brightly stained with the non-toxic membrane dye.
Pece et al., [41] have shown that PKH26 dye retention can
a
b































Fig. 7 Sudden death triggered by
sustained IRES inhibition
documented by live imaging. a
Live cell confocal images of
SUM159 cells treated X 24, 48, or
72 h with 5 μg/ml IRES inhibitor
cpd_P (or vehicle control) under
full serum conditions. Green
calcein AM; Red CMXRos, Blue
Hoescht 33258. Cells were
seeded, treated, stained, and
viewed in 8-well chambered
coverslips (Nunc). Please see the
BMaterials and Methods^ section
for staining protocol. b SUM159
cells were treated with cpd_P at
5 μg/ml for 48 h, at which point i
treatment was continued without
alteration; ii media was changed
and compound removed
(washout); or treatment was
continued following addition of
iii Z-VAD-fmk (final
concentration 20 μM) or iv
necrostatin (final concentration
10 μM). Live cell images were
captured at the 72-h time point. c
Live cell confocal images of
T98G cells treated with 2.5 μg/ml
cpd_P (or vehicle control) for 24
or 48 h under low serum
conditions as indicated. All scale
bars 25 μm
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be used to visualize and distinguish tumor stem cells in situ
among the population of more actively proliferating cells.
Note that although SUM159 is triple negative, highly undif-
ferentiated, and stem-like in nature, it is still hierarchically
organized, and only a small proportion of the cells within
the population are actually stem cells [42, 43].
At 24 h, the vehicle-treated control fields exhibit multiple
bright red candidate stem cells, some of which are intensely
stained for Myc themselves (i.e., yellow), or are otherwise
surrounded by intensely green-(Myc)-stained cells in close
proximity (Fig. 8a). However, for the cells treated with
cpd_P, although viability is not yet compromised, a dramatic
loss of Myc protein from both the candidate stem cells them-
selves, as well as the cells surrounding them is observed. As
Myc is closely tied to stem cell status [44–46], it is conceiv-
able that this depletion of Myc from the stem cells and their
immediate neighbors may undermine the undifferentiated na-
ture and/or compromise the survival of the stem cells. At the
72-h time point, although viable candidate tumor stem cells
can still be seen in the control fields, essentially all such bright
red stem cell candidates treated with cpd_P are dead,
displaying marked chromatin condensation and no esterase-
positive cytoplasm (Fig. 8b).
Death of candidate tumor stem cells is also observed in situ
when T98G cells are treated with the IRES inhibitor (Fig. 8c).
Although it appears that the tumor stem cells are dying in
roughly the same time frame and same manner as the bulk
of the tumor cell population, a more complete understanding
of these events and relationships, i.e., whether it is the tumor
stem cells that drive the differentiation program and trigger the
population-wide cell death event, or whether the bulk tumor
cells are the primary targets of IRES inhibition, with the tumor
stem cells merely becoming integrated into the cellular net-
work and eliminated alongside their progeny, will require fur-
ther investigation.
Discussion
Atypical mode of cell death induced by sustained IRES
inhibition
A working model for the phenotypic consequences of
sustained IRES inhibition (terminal differentiation → syn-
chronized cell death) is illustrated in Fig. 8d. Sustained
IRES inhibition culminates in massive loss of viability of the
malignant cells, yet the response to cpd_P is not like that of a
typical cytotoxic agent. Cell death is preceded by dramatic
alterations in cytoskeletal organization and tissue architecture,
including marked gains in polarity and intercellular connec-
tivity, and formation of tight junctions or neuronal processes,
all of which are characteristics of non-malignant cells.
Furthermore, the changes induced by cpd_P are completely
reversible until a critical threshold in duration of exposure is
reached. The formation of extensive physical interconnections
between the cells is a key feature and likely very important for
mediating both the dramatic phenotypic alteration as well as
the population-wide cell death event that follows. The fact that
loss of viability is so sudden and affects essentially the entire
tumor cell population all within the same time frame distin-
guishes this mode of cell death from typical stochastic pro-
cesses such as apoptosis, necrosis, or autophagy, where cell
death decisions are made at the level of the individual cell.
This phenotypic outcome is even more atypical in that it takes
place concomitantly with a marked decrease (rather than gain)
in p21 and p27. The Hill slope of the dose-response curve is a
reflection of drug mechanism of action, and a Hill slope > ±1
is usually accounted for (in classical enzymology and phar-
macology) by cooperativity [23]. It appears in the case of
IRES inhibition (with Hill slopes in the −15 to −35 range) that
cooperativity is taking place at the cellular level. Cell death is
non-apoptotic, as PARP cleavage is not observed, caspase 3/7
activation is limited, and no protection afforded by addition of
caspase inhibitor Z-VAD-fmk prior to loss of viability. Even
upon cell death, catabolism of cellular structural elements is
limited, loss of cell membrane integrity is delayed, and cellu-
lar disintegration does not occur.
Thus, the atypical mode of cell death induced by sustained
IRES inhibition does not fit any of the classical programmed
cell death outcomes. Instead, this unique phenotypic outcome
most closely resembles cornification, a well-established phys-
iological program in which terminal differentiation is inher-
ently linked with loss of viability [47]. Mailleux et al. have
shown that mammary epithelial cells are capable of utilizing
squamous differentiation or cornification as an alternative
mode of cell death when apoptosis is blocked [48], demon-
strating that this mechanism is not restricted to keratinocytes.
Cornification involves a reduction of cellular water content,
limited proteolytic remodeling of cellular components, and
leaves a structurally intact network of non-viable cells, all
features in common with the breast tumor and glioblastoma
cells subjected to IRES inhibition. In fact, during execution of
the cornification program, premature death of the cells prior to
completion of differentiation is suppressed by anti-apoptotic
and anti-necrotic mechanisms [49]. This could explain the de-
induction of BiP and CHOP, and the apparent failure to re-
spond to stress observed in the cells treated with optimal
differentiation-inducing concentrations of the IRES inhibitor.
Potential therapeutic ramifications of IRES inhibition
Together, these findings support the concept that IRES-
mediated translation is critical for maintenance of the undif-
ferentiated phenotype, and that selective interference with
IRES function has the potential to induce terminal differenti-
ation and trigger population-wide death in otherwise highly
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undifferentiated malignant cells. Induction of terminal differ-
entiation as a means to eradicate malignant cells is an accepted
paradigm for treatment of certain types of leukemia [50, 51].
The results presented here suggest that such a strategy might
also be effective in at least some solid tumors as well, and that
IRES inhibition may be one way to accomplish this.
The hierarchical organization of tumor cells implies that
bidirectional communication or quorum-sensing type mecha-
nisms must be utilized to regulate the equilibrium between
tumor stem cells and their progeny comprising the bulk tumor
cell population. IRES inhibition apparently perturbs this equi-
librium, resulting in synchronous alterations to phenotype
affecting the entire tumor cell population. In fact, our results
are in line with projections generated using mathematical
models simulating the consequences of modulating the fre-
quency with which tumor stem cells undergo symmetrical
versus asymmetrical cell division [27].
The molecular and phenotypic consequences of IRES inhi-
bition are complex. Successful implementation of IRES inhi-
bition as a therapeutic strategy will need to take into account
the unique pharmacodynamic properties of these compounds.
For instance, because the IRES inhibitors are not typical cy-
totoxic agents, but operate instead bymodulating gene expres-
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most effective. Based on the current data, it would appear that
this particular strategy of using IRES inhibition to induce ter-
minal differentiation might work best as an initial treatment
regimen, intended to eliminate tumor stem cells and the bulk
tumor population in parallel, rather than following surgery or
cytotoxic chemotherapy, when the goal is to eradicate small
numbers of disseminated malignant cells.
One of the long-range goals for development of these pro-
totype IRES inhibitors as useful drugs would be widening of
the concentration range at which optimal terminal
differentiation and tumor cell death are obtained, through
chemical optimization of the lead compound. Yet, the inordi-
nately steep dose-response curves associated with the IRES
inhibitors, in which IC50 and IC99 are achieved at nearly the
same concentration, may provide unique pharmacodynamic
benefits over agents with more typical dose-response relation-
ships, where achieving IC99 may be difficult.
Heterogeneity of the tumor cell population is a well-
recognized problem [52], and thought to be a major contribu-
tor to therapeutic failure and disease recurrence [53, 54]. It is
difficult to achieve complete eradication due to cell-to-cell
variability in response. Xia et al. [55] have argued that in terms
of therapeutic agents capable of killing tumor cells, the focus
should be not on what happens to the Baverage^ cell or the
dominant subset, but on the variance among the population.
The apparent homogeneity in response to optimal
differentiation-inducing concentrations of cpd_P suggests that
there may be a tangible kinetic advantage to synchronized
over stochastic tumor cell death, and that this might be one
way to combat inherent intratumoral heterogeneity.
In total, we have tested 17 different human tumor cell lines
representing multiple tumor types, and found the synchro-
nized comprehensive mode of cell death described here to
be induced in 5 of them (∼30 %), including (in addition to
SUM159 and T98G) an osteosarcoma (143B, Suppl. Fig. 2e,
f), as well as another triple-negative breast carcinoma and an
acute myeloid leukemia (BT-20, THP-1, data not shown).
Some of the other cell lines tested exhibited more acute cell
death responses to IRES inhibition (MDA-MB-231 triple-
negative breast carcinoma, NIH:OVCAR-3 ovarian carcino-
ma, SUM149 inflammatory breast carcinoma, Saos-2 osteo-
sarcoma), while a minority of tumor cell lines were highly
resistant to cpd_P (Rh30 rhabdomyosarcoma).
The pattern of response noted in ER-positive breast tumor cell
lines (e.g., T47D, ZR-75-1)was particularly informative.We find
that exposure to cpd_P forces the ER-positive breast tumor cells
to shift to a more differentiated phenotype, but this is not associ-
ated with extensive loss of viability. In fact, the viability data for
the ER-positive cell lines are nearly superimposable with that of
the normal human mammary epithelial cells (presented in Suppl.
Fig. 2c, d). Importantly, however, we also find that clonogenic
survival and mammosphere formation by the ER-positive cell
lines are potently inhibited by cpd_P. These assays measure the
impact of IRES inhibition on the small fraction of tumor cells
with colony-forming or mammosphere-forming capacity, i.e.,
putative tumor stem cells. Thus, while the bulk of the tumor cell
population (already moderately differentiated) is relatively resis-
tant, the tumor stem cells underlying ER-positive breast cancer,
which are actually ER-negative [56] and highly undifferentiated,
appear to be highly sensitive to IRES inhibition (manuscript in
preparation). Of note, death of the tumor stem cells associated
with ER-positive breast cancer cell lines in response to IRES
inhibition does not appear to be synchronized, nor exhibit
Fig. 8 Death of putative tumor stem cells visualized in situ in association
with IRES inhibition. a SUM159 cells were stained with PKH26 (red),
washed extensively, and allowed 7 days to propagate and distribute
(dilute) the dye to daughter cells at each mitotic event. Cells were then
seeded onto 8-well chamber slides, allowed 48 h to recover and resume
proliferation, then treated with cpd_P (or vehicle control) in full serum at
5 μg/ml for 24 h. Cells were fixed, permeabilized (using saponin in place
of Triton X-100 to protect PKH26), and stained for Myc (green) and
DAPI. Fields containing bright red-stained candidate tumor stem cells
were imaged, and four such representative fields are shown for each
condition. Overlap of green and red fluorescence produces a yellow
signal (i.e., a stem cell with high Myc content). b PKH26 (red)-stained
SUM159 cells described earlier were seeded in 8-well chambered
coverslips, allowed 48 h to recover and resume proliferation, then treated
in full serum-containing media with cpd_P at 5 μg/ml or DMSO control
for 72 h. Calcein AM and Hoescht 33258 were added to the media, and
live cell images captured, concentrating on fields containing bright
red-stained stem cell candidates. Three such representative fields are
shown for each condition. c T98G cells were stained with PKH26 (red),
and allowed 7 days to propagate and distribute the dye to daughter cells,
then seeded onto 8-well chamber slides, allowed 48 h to recover and
resume proliferation, and treated with cpd_P (or vehicle control) at
2.5 μg/ml for 48 h in low (0.5 %) serum media. Cells were stained for
β-III tubulin (green) and Hoescht 33258. Fields containing bright
red-stained candidate tumor stem cells were imaged, and three such
representative fields are shown for each condition. All settings, including
PMT voltage, laser power, and pinhole diameter were held constant
during image capture of related samples, except for calcein AM, which
required constant adjustment in accordance with real-time variations in
metabolism by live cells. All scale bars 25 μm. d Aworking model for
the phenotypic consequences of sustained IRES inhibition in malignant
cells. Initially, the tumor cells exhibit no structural organization or
polarization and are haphazardly arranged on the growth surface.
Continuous exposure to the IRES inhibitor induces terminal differentia-
tion (or a phenotypic alteration closely resembling terminal differentia-
tion), as a result of perpetual inability to synthesize certain key gene
products (e.g., Myc) necessary to maintain the undifferentiated pheno-
type. A marked gain in structural organization is readily appreciated. Cell
death is triggered suddenly i upon restoration of normal homeostatic
mechanisms which detect the underlying abnormalities that cause the
cells to be malignant, or ii perhaps because these otherwise highly undif-
ferentiated malignant cells may not tolerate the transition to a fully dif-
ferentiated state, or iii alternatively because such an outcome is an integral
part of execution of a program related to cornification, where terminal
differentiation and cell death are inherently linked. Once triggered, cell
death is rapid and comprehensive, resulting in massive loss of viability
affecting the entire tumor cell population. Cell death is atypical, with the
network of dead cell corpses remaining structurally intact. Tumor stem
cells (denoted by red color) are eliminated along with the bulk of the
tumor cell population, consequently, there is no capacity to rebound and
repopulate
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features of terminal differentiation, and is favored by low rather
than high cell density.
Thus, the synchronized comprehensive mode of cell death
is not an invariant outcome of IRES inhibition in all human
tumor types. Rather, the data indicate that IRES inhibition has
the capacity to induce terminal differentiation and population-
wide cell death in susceptible cells under the appropriate con-
ditions. Ultimately, it will be important to characterize the
factors which cause certain tumors to be susceptible to trig-
gering of synchronized comprehensive cell death in response
to IRES inhibition, and to establish specific biomarkers which
can be used to distinguish those tumors.
Conclusion
The identification of the prototype IRES inhibitors allows us to
begin to dissect the relationship between IRES-mediated trans-
lation and the malignant phenotype, and begin to determine
what might be accomplished by pharmacologically modulating
this specializedmode of protein synthesis.We have learned that
in susceptible cells at optimal intermediate concentrations of
cpd_P, a population-wide phenotypic alteration resembling ter-
minal differentiation is induced, followed closely by a synchro-
nized comprehensive cell death event which eliminates all or
very nearly all of the tumor cells. At higher concentrations of
the IRES inhibitor, factors such as IGF1R and connexin 43may
be lost, BiP and CHOP are induced, terminal differentiation is
incomplete, and the synchronized comprehensive cell death
event is not triggered, but is replaced instead by a more pro-
gressive, stochastic loss of viability affecting individual cells.
Further investigation will be needed to identify precisely all of
the factors involved in mediating this outcome, but as a first
approximation, it appears the synchronized comprehensive
mode of cell death is the result of an intrinsically synthetic
lethal combination of changes in IRES-driven proteins (includ-
ing but not limited to Myc) whose translation is altered by the
small-molecule inhibitor.
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